Proceedings in Obstetrics and Gynecology

Authors

Shujie Yang, University of IowaFollow
Xue Xiao, University of Iowa
Xiangbing Meng, University of Iowa
Kimberly K. Leslie, University of Iowa

Article Title

Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells

Abstract

Dysregulation of mammalian target of rapamycin (mTOR) signaling has been found in many human tumors, including endometrial cancer, and mTOR inhibitors have been utilized in clinical trials as targeted therapies with only limited success. Herein we identify a viable treatment alternative that overcomes temsirolimus-induced AKT phosphorylation in endometrial cancer. Our data suggest temsirolimus and BEZ235 inhibit different components of the AKT/mTOR signaling pathway to accomplish synergistic pathway inhibition, which is necessary for therapeutic efficacy to abrogate the increased signaling through AKT that occurs with mTOR inhibition alone

Keywords

PI3K, Akt, mammalian target of rapamycin, temsirolimus, BEZ235, endometrial cancer

Submission Type

Article

Creative Commons License

This work is licensed under a Creative Commons Attribution 3.0 License.

Recommended Citation

Yang S, Xiao X, Meng X, Leslie KK. Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells. Proc Obstet Gynecol. 2011 Jul 28;2(1):Article 6 [2 p.]. Available from: http://ir.uiowa.edu/pog/vol2/iss1/6. Free full text article.